IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens

Table 5

Comparison of SVR and non-SVR patients treated with peginterferon, ribavirin, and telaprevir by univariate analysis (a) and multivariate analysis (b).

(a) Univariate analysis

	SVR,	Non-SVR,	values (SVR versus non-SVR groups)
Gender, male/female	24/8	5/2	0.77
Age, years	57.8 ± 9.3	59.8 ± 5.6	0.58
Previous treatment: naïve/relapse/null	14/17/1	3/2/2	0.13
AST, IU/L	55.9 ± 50.1	44.7 ± 16.0	0.56
ALT, IU/L	71.9 ± 70.6	51.1 ± 19.9	0.44
γ-GTP, IU/L	62.1 ± 64.7	46.2 ± 27.9	0.53
Hemoglobin, g/dL	14.6 ± 1.3	14.4 ± 1.6	0.72
Platelets, ×10^4/mm^3	16.4 ± 5.2	14.3 ± 4.6	0.33
HCV RNA ()	6.45 ± 0.68	6.81 ± 0.75	0.220
Treatment response
RVR,	27	0	<0.0001
EVR,	32	2	<0.0001
IFNL4, major/minor/ND	22/8/2	2/5/0	0.0727

Null: null response; AST: aspirate aminotransferase; ALT: alanine aminotransferase; γ-GTP: γ-glutamyltransferase; RVR: rapid virological response; EVR: early virological response; SVR: sustained virological response.

(b) Factors associated with SVR among patients treated with peginterferon, ribavirin, and telaprevir by multivariate analysis

Factor	Category	Odds ratio	95% CI	values
HCV RNA (log IU/mL)	<6.4/6.4≤	13.74	1.014–186.30	0.048
IFNL4; ss469415590	major/minor	17.54	1.980–156.25	0.010